Associations of Anemia, Treatments for Anemia, and Survival in Patients with Human Immunodeficiency Virus Infection
|
|
- Grace Washington
- 6 years ago
- Views:
Transcription
1 S138 Associations of Anemia, Treatments for Anemia, and Survival in Patients with Human Immunodeficiency Virus Infection Patrick Sullivan Fred Hutchinson Cancer Research Center, Seattle, Washington Introduction Three large observational cohort studies suggest that, after controlling for virus load and CD4 cell count, anemia is related to disease progression and survival in patients with human immunodeficiency virus (HIV) infection. Recovery from anemia has been linked to improved survival outcomes. Blood transfusion has been associated with accelerated disease progression and mortality in patients with HIV infection, and review of related literature suggests that the mechanism for negative transfusion-associated outcomes may be transfusion-related immunosuppression. Therefore, the use of transfusion should be restricted to patients with acute or severe anemia. Prescription of epoetin alfa has been associated with increased survival in an observational cohort among patients with HIV infection and anemia. In the absence of data from a clinical trial documenting the effect of treating anemia on survival, clinicians should consider non-transfusion options for management of anemia on the basis of clinical status and patient functional ability. Plasma virus load and CD4 cell count are important prognostic markers that are commonly used in the management of patients with human immunodeficiency virus (HIV) infection and AIDS [1 3]. In addition, other factors, such as opportunistic infections [4 9], serum albumin concentrations [10, 11], markers of immune activation [12, 13], loss of body weight [10], and patient age [14, 15], have been associated with clinical outcomes of HIV disease. These factors differ widely in the degree to which they accurately and independently predict disease progression or survival. In some cases, such factors may have a causal relationship with decreased survival; in others, factors may be markers for severe or progressive HIV disease. Recent epidemiologic studies of HIV-related anemia have strongly and repeatedly associated low hemoglobin level with disease progression and mortality [15 22]. Patients who are at greater risk for anemia may include those of African-American ancestry, and those with low CD4 cell counts, high virus load, and low mean corpuscular volume and those receiving zidovudine [18, 23, 24]. While the association between anemia and decreased survival in HIV infection has not been proven to be causal, the consistent findings of large observational cohort studies suggest that hemoglobin level is an important factor in understanding the clinical course of patients living with HIV infection. Reprints or correspondence: Dr. Patrick Sullivan, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, Mailstop MW-500, Seattle, WA The Journal of Infectious Diseases 2002;185(Suppl 2):S q 2002 by the Infectious Diseases Society of America. All rights reserved /2002/18510S-0007$02.00 Association of Anemia and Survival The results of multiple epidemiologic studies suggest that HIVinfected patients with anemia are at a greater risk for mortality than are patients without anemia, even after controlling for various factors known to affect survival, such as virus load or CD4 cell count. The Centers for Disease Control and Prevention (CDC) conducted an analysis of data from a large observational cohort study that collected information from the medical records of 32,867 HIV-positive patients who were treated at hospitals, clinics, and private medical practices throughout the United States between January 1990 and August 1996 [18]. Anemia was defined as a hemoglobin level,10 g/dl or a diagnosis of anemia based on the International Classification of Diseases-9 diagnosis codes ( , , , and ) [25]. That study showed that in the 19,213 patients with HIV infection, median survival was significantly shorter for patients with anemia than for those without anemia (P, :0001) (table 1). This phenomenon occurred regardless of CD4 cell count, clinical AIDS, age, neutropenia, thrombocytopenia, antiretroviral therapy, or Pneumocystis carinii pneumonia (PCP) prophylaxis. Of note, the association of anemia and survival varied by the first CD4 cell count. Thus, although the hazard of dying was greater in patients who developed anemia for all CD4 strata, the hazard associated with anemia increased as CD4 cell counts increased (table 1). For example, the hazard of death among patients with incident anemia was for CD4 cell counts of,200 cells/ml, versus 2.5 for CD4 cell counts of >200 cells/ml. The EuroSIDA study group conducted an analysis of retrospective observational cohort data collected in Europe and reported a wide variation in clinical outcome among 6725 patients with normal hemoglobin levels, mild anemia, or severe anemia at baseline [16]. Normal hemoglobin levels were defined as levels.14 g/dl for men and.12 g/dl for women. Mild anemia was defined as hemoglobin levels of 8 14 g/dl for men and 8 12
2 JID 2002;185 (Suppl 2) Anemia, Treatments, and Survival in HIV S139 Table 1. Association of anemia and survival in 19,213 HIV-infected patients [18]. Median survival (months) CD4 stratum (cells/ml) Anemia (99% CI) No anemia (99% CI) Risk ratio a (99% CI) P b (12 12) 15 (15 17) 1.4 ( ) (19 21) 25 (22 29) 1.4 ( ) (24 28) 33 (29 40) 1.4 ( ) (26 32) 48 (40 58) 1.9 ( ).0001 > (46 51) c 2.5 ( ).0001 NOTE. CI, confidence interval. a Hazard of death associated with incident anemia in a Cox proportional hazards regression model. b P values are from the log rank test. c Unable to calculate median survival because of low death rate. g/dl for women. Severe anemia was defined as hemoglobin levels of,8 g/dl for men or women. Kaplan-Meier estimates were established for the proportion of patients who died in the months after first observation (figure 1). For patients without anemia, 3.1% died by 12 months. In contrast, for patients with mild anemia, 15.9% had died, and for patients with severe anemia, 40.8% had died. The difference among the 3 groups was statistically significant (P, :001, log-rank test). In proportional hazards regression models controlling for HIV RNA concentration and CD4 cell count, the hazard of death was increased by 57% (relative hazard, 1.57; 95% confidence interval [CI], 1.41% 1.75%; P, :0001) for each 1-g/dL reduction in hemoglobin. Moore et al. [15] analyzed the relationship between hemoglobin levels and survival in 2343 HIV-infected patients. Anemia was defined as a hemoglobin level of,9.5 g/dl. Their results indicated that the development of anemia was associated with a significantly greater risk of death (P ¼ :0001). This association was independent of CD4 cell count, development of selected opportunistic infections, age, and the use of antiretroviral and opportunistic infection drug therapies. On the basis of criteria for anemia used by the AIDS Clinical Trials Group, patients with grade 3 or 4 anemia had hazard estimates for mortality of 3.8 (95% CI, ) (table 2). The findings from these epidemiologic studies provide consistent evidence of an association between anemia and mortality in HIV-infected patients. Two important questions arise from these findings: Can treatment of anemia modify this relationship and improve clinical outcome, and is there a causal association between anemia and mortality in HIV infection? level that was >1 g/dl higher than that seen at the time that anemia was diagnosed, thus permitting an assessment of the association of amelioration of anemia and clinical outcome. Recovery from anemia was significantly associated with a reduced risk of death (P ¼ :001, log-rank test), even after controlling for clinical AIDS diagnosis, CD4 cell count, neutropenia, thrombocytopenia, antiretroviral therapy, and PCP prophylaxis (figure 2). For example, median survival for patients with CD4 cell counts of cells/ml was 31 months for those who recovered from anemia, 18 months for those who did not recover from anemia, and 25 months for those who never developed anemia. For patients with CD4 cell counts of at least 200 cells/ml, recovery from anemia was associated with a median survival of 64 months, compared with 36 months for those who did not recover from anemia (P ¼ :0001). Using data from 2343 HIV-infected patients, Moore et al. [15] described the results for 91 patients with anemia (hemoglobin level,9.5 g/dl) who were treated with epoetin alfa for an average of 6 months (range, 2 weeks to 28 months). Patients treated with epoetin alfa experienced improved hemoglobin levels (mean increase, 1.5 g/dl; range, ). The use of epoetin alfa was associated with a significantly reduced risk of death (relative hazard, 0.57; range, ; P ¼ :002) compared with no epoetin alfa treatment. The survival benefit associated with epoetin alfa was maintained even after controlling for other variables with known prognostic value. Is the Relationship between Anemia and Survival in HIV Infection Causal? Although epidemiologic findings are important, they are limited in their ability to substantiate causality. Observational cohort studies do not randomly assign patients to anemic or non-anemic status and do not randomly assign treatment or placebo for those Association of Recovery from Anemia and Survival In the observational cohort study conducted by the CDC, subsequent hemoglobin levels were available for 3203 anemic patients (hemoglobin,10 g/dl) [18]. Of these patients, 1341 (42%) were treated with either recombinant human erythropoietin (epoetin alfa) or blood transfusion, and 1208 (38%) recovered from anemia (hemoglobin >10 g/dl) and achieved a hemoglobin Figure 1. Kaplan-Meier curve of time to death in HIV-infected patients with normal hemoglobin (Hb), mild anemia, or severe anemia in the EuroSIDA study. Reprinted with permission from [16]. The indicated P value is a log-rank statistic.
3 S140 Sullivan JID 2002;185 (Suppl 2) Table 2. Association of anemia and survival in 2343 HIV-infected patients [15]. Anemia grade a (hemoglobin level) Relative hazard (95% CI) b P c 1 ( g/dl) 3.06 ( ) ( g/dl) 2.90 ( ) and 4 (,6.9 g/dl) d 3.80 ( ).0001 NOTE. CI, confidence interval. a The severity of the anemia was based on hemoglobin levels used by the AIDS Clinical Trials Group. b Hazard of death associated with incident anemia in a Cox proportional hazards regression model. c P values are from the log rank test. d Grades 3 and 4 were combined to increase the power of the analysis. patients who develop anemia. Thus, the questions of whether the relationship between anemia and decreased survival for people with HIV infection is causal and whether aggressive treatment of anemia may be associated with survival benefit cannot be answered conclusively by an observational cohort study. To assess causality when only results from observational studies are available, epidemiologists rely on at least 6 criteria [26, 27]: consistency among studies, dose-response effect, coherence (biologic plausibility), strength of association, exposure precedes disease, and specificity of association. In the case of the results of studies of anemia and HIV infection, satisfaction of 5 of these criteria is consistent with a causal relationship. In short, there is consistency across the epidemiologic studies conducted to date; there is a dose-response effect such that greater grades of anemia are associated with greater risk of mortality; the relationship is strong and independent of other variables; causality is biologically plausible (coherence); and in the analytical design, the exposure (anemia) precedes the outcome (death). The criterion of specificity of the association (i.e., the putative causative agent is both necessary and by itself sufficient to result in the outcome) is infrequently satisfied, even in relationships where causality is clear. Although many of the traditional criteria for causality are met, there exists the possibility of biases, including survival bias, which might result in data that suggest a causal relationship where one does not in fact exist. A prospective, randomized clinical trial would be required to evaluate the practical consequence of the question of causality: Does a particular intervention to correct anemia improve survival? If the relationship between anemia and survival is not causal, then anemia may be a marker for some aspect of progressive HIV disease that is not measured by CD4 cell count or HIV RNA concentration. In the latter case, even if the relationship between anemia and shorter survival is not causal, anemia represents an important clinical consideration for providers caring for patients with HIV infection and an important area for further research. Data from a randomized clinical trial would ultimately best inform evidence-based recommendations for management of anemia in patients with HIV infection. Association of Treatments for Anemia and Survival The cohort study by Moore et al. [15] evaluated the survival effects of blood transfusion and epoetin alfa prescription among persons with HIV infection and anemia. The results of that analysis indicated that blood transfusion was associated with shorter survival, while epoetin alfa prescription was associated with improved survival. A follow-up analysis of data from the same cohort in the late 1990s was reported, with similar results [19]. A review of related literature suggests mechanisms that may explain these observed associations. The standard treatment for acute, severe, or life-threatening anemia is blood transfusion, and the main advantage of this modality compared with drug therapy is rapid recovery from anemia with relief of symptoms [28]. However, blood transfusion, even early in the course of HIV disease, has been associated with increased risk of death [15, 19, 29] and death rate [30] for patients with HIV infection. There are several hypotheses that might explain this phenomenon, including the risk for transfusion-associated infection with another infectious agent, transfusion-associated immunosuppression, or activation of HIV replication. Although current screening practices have resulted in marked reduction in the risk of transfusion transmission of HIV, hepatitis B virus, hepatitis C virus, and human T cell lymphotropic viruses I/II, there are still risks of infection with other agents, such as cytomegalovirus or parvovirus B19 [31 33]. Transfusionassociated immunosuppression, thought to be mediated by inflammatory cytokines, is demonstrated by a reduced function in Figure 2. Median survival time from baseline CD4 cell count, stratified by whether the patient recovered from anemia, and first observed CD4 cell count among 3203 persons with anemia (hemoglobin,10 g/dl) and HIV infection [18]. Bars indicate median survival times; the indicated P value is a log-rank statistic. Nos. appearing below each CD4 stratum indicate the hazard of death (with 99% confidence intervals [CI]) associated with recovering from anemia (defined as hemoglobin >10 g/dl and an increase in hemoglobin of at least 1 g/dl) in a Cox proportional hazards regression model for patients in that CD4 cell stratum. Data from [18].
4 JID 2002;185 (Suppl 2) Anemia, Treatments, and Survival in HIV S141 lymphocytes, natural killer cells, and monocytes [34 36]. Transfusion has been associated with the recurrence of malignancy in persons with colorectal cancer and with prolonged allograft survival in patients with renal transplants, both of which would be predicted from putative transfusion-associated immunosuppression. Last, transfusion has been associated with the transient activation of HIV expression [37, 38]. Although the clinical significance of brief break-through cycles of HIV replication is not clear and vaccine-associated activation of HIV expression seems not to be associated with decreased survival [39], active HIV replication in the context of antiretroviral therapy represents an opportunity for development of resistance, which could in turn be associated with reduced survival. Although transfusion is clearly appropriate and important for patients with acute blood loss or severe or life-threatening anemia, these findings suggest that for patients with HIV infection and less acute or severe anemia, non-transfusion options for management of anemia, including epoetin alfa, should be considered; clinical evaluation and transfusion and non-transfusion options are discussed in detail elsewhere (see article by S. Claster in this supplement). This conclusion is also consistent with current transfusion recommendations [33], which assert that blood transfusion should not be administered on the basis of a trigger hemoglobin set point but should be based on the patient s risk of developing inadequate oxygenation [40] and that avoidance of transfusion [should be] the ideal, to the extent that avoidance [is] not likely to be a more serious risk than the transfusion [33]. The question of whether prescription of epoetin alfa may be plausibly causally associated with improved survival may also be considered in the context of evidence from clinical trials of patients with cancer-associated and renal anemia. In a recently reported randomized, double-blind, placebo-controlled trial to evaluate the effects of epoetin alfa on hematologic parameters for patients with cancer (solid or non-myeloid hematologic malignancies)-related anemia, there was a trend in overall survival favoring epoetin alfa [41]. Other studies have suggested that use of epoetin alfa may improve survival outcomes for patients with renal anemia and early-stage cardiac disease [42] and for patients undergoing chemoradiation for head and neck tumors [43]. The mechanisms suggested to substantiate plausibility in these studies have included cellular compromise (impaired cellular oxygenation) and general patient compromise (decreased quality of life and treatment delivery) [44]. Conclusions The results of multiple epidemiologic studies suggest an inverse relationship between anemia and survival in patients with HIV infection. Conversely, recovery from anemia is associated with better survival outcomes. The nature of the relationship between anemia and survival is not completely defined by these studies, and a randomized clinical trial would be required to make definitive recommendations regarding the potential survival benefit of managing anemia aggressively. Available evidence suggests that blood transfusion for the management of anemia in patients with HIV infection is associated with accelerated mortality, plausibly because of transfusion-related immunosuppression. These findings should be interpreted in the broader context of knowledge about anemia and quality of life (see article by P. Volberding in this supplement) and of available non-transfusion options for management of anemia (see article by S. Claster in this supplement). References 1. Mellors JW, Kingsley LA, Rinaldo CRJ, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 þ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 þ cell count. JAMA 1998;279: Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998;12: Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia in the United States. J Infect Dis 2001;183: Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000;31: Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus infected patients in the protease inhibitor era. J Infect Dis 1999;180: Baillargeon J, Borucki MJ, Williamson J. Temporal trends in AIDSrelated survival. AIDS Patient Care STDS 1999;13: Baillargeon J, Borucki M, Black SA, Dunn K. Determinants of survival in HIV-positive patients. Int J STD AIDS 1999;10: Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8: Feldman JG, Burns DN, Gange SJ, et al. Serum albumin as a predictor of survival in HIV-infected women in the Women s Interagency HIV study. AIDS 2000;14: Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8 þ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4 þ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16: Sabin CA, Devereux H, Phillips AN, Janossy G, Loveday C, Lee CA. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998;12: Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7: Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29 33.
5 S142 Sullivan JID 2002;185 (Suppl 2) 16. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999;13: Chene G, Easterbrook PJ, Juszczak E, Yu LM, Pocock SJ, Gazzard BG. Long-term survival in patients with advanced immunodeficiency. AIDS 1997;11: Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV) infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998;91: Moore RD, Keruly JC, Chaisson RE. Improved survival with correction of anemia in HIV disease [abstract 706]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago, 31 January to 4 February 1999). Alexandria, VA: Foundation for Retrovirology and Human Health. Available at default.htm. 20. Creagh T, Mildvan D, Moore R, Bohn H, Yarrish R, Ray L. A case-control study examining the association of disease prognosis with the development and treatment of anemia in patients infected with HIV-1: interim results [abstract 304]. In: Program and abstracts of the 12th National HIV/ AIDS Update Conference (San Francisco, 2000). New York: The American Foundation for AIDS Research, Lundgren JD, Mocroft A, Gatell JM, et al. The change in risk of clinical progression after initiation of HAART: the EuroSIDA study [abstract 1905]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, September 2000). Washington, DC: American Society for Microbiology, Lewden C, Leport C, Cuzin L, et al. Prognostic factors of mortality in the APROCO-ANRS EP11 cohort of HIV-1 infected adults started on a protease inhibitor containing therapy [abstract 1909]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, September 2000). Washington, DC: American Society of Microbiology, Berhane K, Sanchez L, Masri-Lavine L, et al. Relationship between highly active anti-retroviral therapy (HAART) and anemia in a large cohort of HIV infected women (Women s Interagency HIV Study WIHS) [abstract 2457]. In: Proceedings of the American Society of Clinical Oncology (New Orleans, 2000). Alexandria, VA: American Society of Clinical Oncology, Sharp V, Paredes J, Steinbock C. Anemia in HIV disease in the HAART era: is it common? Blood 1999;94:8b. 25. St. Anthony s Softbound ICD 9 CM Code Book. Reston, VA: St. Anthony Publishing, 1998: Mausner JS, Kramer S. Epidemiology an introductory text. 2d ed. Philadelphia: WB Saunders, 1985: Rothman KJ. Modern epidemiology. Boston: Little Brown & Co, 1986: Henry DH. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia. Semin Oncol 1998;25: Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33: Sloand E, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994;34: Moor AC, Dubbleman TM, VanSteveninck J, Brand A. Transfusion-transmitted diseases: risks, prevention and perspectives. Eur J Haematol 1999;62: Hillyer CD, Lankford KV, Roback JD, Gillespie TW, Silberstein LE. Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, -7, and -8. Transfus Med Rev 1999;13: Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J 1997;156(Suppl): S1 24. Available at index.htm. 34. Kirkley SA. Proposed mechanisms of transfusion-induced immunomodulation. Clin Diagn Lab Immunol 1999;6: Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev 1990;4: Blumberg N, Heal JM. Transfusion and recipient immune function. Arch Pathol Lab Med 1989;113: Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992;80: Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36: Sullivan PS, Hanson DL, Dworkin MS, et al. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000;14: Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84: Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: Parfrey P. Anaemia in chronic renal disease: lessons learned since Seville Nephrol Dial Transplant 2001;16(Suppl): Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 2001;38(Suppl): Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28:49 53.
3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression Bryan Lau, PhD, MHS, ScM; A. Richey Sharrett, MD, DrPH; Larry A. Kingsley, DrPH; Wendy Post, MD,
More informationThe importance of cohort collaborations for guiding clinical management of individuals with HIV infection
The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationAntiviral Therapy 14:
Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm
More informationThe. JOHN GLASPY, a,e LAURENT DEGOS, b,e MARIO DICATO, c,e GEORGE D. DEMETRI d,e LEARNING OBJECTIVES ABSTRACT
The Oncologist Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy: A Retrospective Subanalysis of Two Large, Community-Based Trials JOHN
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationJMSCR Vol 3 Issue 10 Page October 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i10.20 Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral
More informationSimbarashe Takuva, 1 Mhairi Maskew, 2 Alana T. Brennan, 3 Ian Sanne, 1,2 A. Patrick MacPhail, 1,2 and Mathew P. Fox 2,3,4. 1.
Tropical Medicine Volume 2013, Article ID 162950, 6 pages http://dx.doi.org/10.1155/2013/162950 Clinical Study Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationOutcomes of Moderate-to-Severe Pneumocystis Pneumonia Treated with Adjunctive Steroid in Non-HIV-Infected Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2011, p. 4613 4618 Vol. 55, No. 10 0066-4804/11/$12.00 doi:10.1128/aac.00669-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Outcomes
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationCONCISE COMMUNICATION
611 CONCISE COMMUNICATION Risk for Preventable Opportunistic Infections in Persons with AIDS after Antiretroviral Therapy Increases CD4 + T Lymphocyte Counts above Prophylaxis Thresholds Mark S. Dworkin,
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationABSTRACT. Keywords: Chemotherapy induced anaemia, gastrointestinal cancers, India.
An Open Labeled Two Arm Study to Evaluate the Feasibility, Quality of Life, Safety and Efficacy of Darbepoetin as Compared to Erythropoietin Inpatients with Chemotherapy Induced Anemia in Patients with
More informationDecreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral
CONCISE COMMUNICATION Decreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral therapy Andrew E. Grulich, Yueming Li, Ann M. McDonald, Patricia K.
More informationRegulatory Status FDA-approved indications: Valcyte is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.22 Subject: Valcyte Page: 1 of 5 Last Review Date: December 8, 2017 Valcyte Description Valcyte (valganciclovir)
More informationDecline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants
Decline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants Javier Chinen, Baylor College of Medicine Kirk Easley, Emory University Herman
More informationMortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy
HIV/AIDS MAJOR ARTICLE Mortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy Rakhi Kohli, 1,a Yungtai Lo, 2 Andrea A. Howard, 1,2 Donna
More informationABSTRACT Background It is unclear whether there are differences
INITIAL PLASMA HIV-1 RNA LEVELS AND PROGRESSION TO AIDS IN WOMEN AND MEN TIMOTHY R. STERLING, M.D., DAVID VLAHOV, PH.D., JACQUIE ASTEMBORSKI, M.H.S., DONALD R. HOOVER, PH.D., M.P.H., JOSEPH B. MARGOLICK,
More informationA Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY
More informationOCCURRENCE OF PNEUMOCYSTIS PNEUMONIA IN HIV-INFECTED PATIENTS AND THE INTERFERENCE OF THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Received: August 24, 2007 Accepted: December 6, 2007 Abstract published online: December 17, 2007 Full paper published online: March 8, 2008 J. Venom. Anim. Toxins incl. Trop. Dis. V.14, n.1, p.152-160,
More informationHematological profile of people living with HIV infection in Government Dharmapuri Medical College, Dharmapuri
Original Research Article Hematological profile of people living with HIV infection in Government Dharmapuri Medical College, Dharmapuri M. S. Shruthi 1, T. Elavarasan 2*, R. D. Puvitha 2 1 Assistant Professor
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationEstimating the proportion of patients infected with HIV who will die of comorbid diseases
The American Journal of Medicine (2005) 118, 890-898 CLINICAL RESEARCH STUDY Estimating the proportion of patients infected with HIV who will die of comorbid diseases R. Scott Braithwaite, MD, a Amy C.
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationPrognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users
Prognostic Indicators for AIDS and in HIV-Infected Injection Drug Users Plasma Viral Load and CD4 + Cell Count David Vlahov, PhD; Neil Graham, MD; Donald Hoover, PhD; Colin Flynn, ScM; John G. Bartlett,
More informationAnemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies
HIV/AIDS MAJOR ARTICLE Anemia in HIV Infection: Clinical Impact and Evidence-Based Management Strategies Paul A. Volberding, 1,a Alexandra M. Levine, 2,a Douglas Dieterich, 4 Donna Mildvan, 5 Ronald Mitsuyasu,
More informationORIGINAL INVESTIGATION. A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4 + Cell Counts in HIV-Infected Patients
ORIGINAL INVESTIGATION A Critical Assessment of the Prognostic Value of HIV- RNA Levels and CD + Cell Counts in HIV-Infected Patients Sabine Yerly, MS; Thomas V. Perneger, MD, PhD; Bernard Hirschel, MD;
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationTrends in HIV Incidence Among Young Adults in the United States
Trends in HIV Incidence Among Young Adults in the United States Philip S. Rosenberg, PhD; Robert J. Biggar, MD Context. Behaviors that result in potential exposure to human immunodeficiency virus (HIV)
More informationMethods. Linking three datasets BRIEF COMMUNICATION
BRIEF COMMUNICATION Changes in Causes of Death and Associated Conditions Among Persons with HIV/AIDS After the Introduction of Highly Active Antiretroviral Therapy in Taiwan Tsung-Hsueh Lu, Hong-Jen Chang,
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationOral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy
HIV Medicine (2004), 5, 50 54 ORIGINAL RESEARCH r 2004 British HIV Association Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy I Dunic, 1 S Vesic
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationTrends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection
The Open AIDS Journal, 2011, 5, 113-118 113 Open Access Trends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection Patrick S. Sullivan *,1,2, Debra L Hanson
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationMortality rates among injection drug users (IDUs) have been historically high and are still significantly higher
HIV/AIDS MAJOR ARTICLE Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs Roberto Muga,
More informationAIDS at 25. Epidemiology and Clinical Management MID 37
AIDS at 25 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Regional HIV and
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationLow immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease
Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Shailesh K. Choudhary 1 *, Nienke Vrisekoop 2 *, Christine A. Jansen 2, Sigrid A. Otto 2, Hanneke
More informationTrends in Malignancies Among HIV-Infected Patients. Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center
Trends in Malignancies Among HIV-Infected Patients Roger Bedimo, MD, MS VA North Texas Health Care System UT Southwestern Medical Center Denver, April 2011 Learning Objectives At the conclusion of this
More informationIncomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
MAJOR ARTICLE HIV/AIDS Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment Colleen F. Kelley, 1,a Christina M. R. Kitchen, 2,a Peter
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationMiriam Kimel, PhD, Nancy K. Leidy, PhD, Sally Mannix, BA, Julia Dixon, BS
Volume 11 Number 1 2008 VALUE IN HEALTH Does Epoetin Alfa Improve Health-Related Quality of Life in Chronically Ill Patients with Anemia? Summary of Trials of Cancer, HIV/AIDS, and Chronic Kidney Disease
More informationIN the United States, human immunodeficiency virus
Vol. 333 No. 12 RACE, SEX, DRUG USE, AND PROGRESSION OF HIV DISEASE 751 RACE, SEX, DRUG USE, AND PROGRESSION OF HUMAN IMMUNODEFICIENCY VIRUS DISEASE RICHARD E. CHAISSON, M.D., JEANNE C. KERULY, B.S.N.,
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationAIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37
AIDS at 30 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Adults and children
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationTitle: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years
06-ID-02 Committee: Infectious Disease Title: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years Statement of problem: Advances in HIV
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationProteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral- Naive HIV-Infected Subjects
BRIEF REPORT Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral- Naive HIV-Infected Subjects Samir K. Gupta, 1 Lauren Komarow, 2 Roy M. Gulick, 4 Richard B. Pollard, 5 Gregory K.
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationKaposi s Sarcoma. Akifumi IMAMURA. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital AIDS
**3 The Japanese Society for AIDS Research The Journal of AIDS Research :Human herpesvirus 2 HHV-2 Kaposi s Sarcoma Akifumi IMAMURA Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
More informationImmune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy Jaime Robertson, 1 Matthew Meier,
More informationChapter 8. Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates
Slower CD4 T cell decline in Ethiopian versus Dutch HIV 1 infected individuals is due to lower T cell proliferation rates Nienke Vrisekoop *1, Belete Tegbaru *1,2, Margreet Westerlaken 1, Dawit Wolday
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More information[RH], ; 95% ; P
1086 Human Immunodeficiency Virus Rebound after Suppression to!400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression
More informationErythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in
Erythropoiesis stimulationg agents: evidence for their use for the treatment of anemia in thoracic tumors and MICU Dr Dipesh Maskey Senior Resident Dept of Pulmonary & CCM 14 th Oct 2011 Anemia and cancer
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationSpecific Requirements
Specific Requirements AIMS Specific requirements your patients have for transfusion and how this is managed Classify which patients require: Irradiated components CMV negative components Washed components
More informationWeekly. August 8, 2003 / 52(31);
Weekly August 8, 2003 / 52(31);735-739 Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
More informationMORTALITY TRENDS OF HIV-INFECTED PATIENTS AFTER THE INTRODUCTION
MORTALITY TRENDS OF HIV-INFECTED PATIENTS AFTER THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: ANALYSIS OF A COHORT OF 3,322 HIV-INFECTED PERSONS Introduction: The implementation of highly active
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationPotential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.
In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress
More informationClinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Valcyte) Reference Number: CP.CPA.116 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationOI prophylaxis When to start, when to stop. Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco
OI prophylaxis When to start, when to stop Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco Learning Objectives o Recognize when to start OI prophylaxis
More informationReduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More informationRegulatory Status FDA approved indications: Valctye is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.22 Subject: Valcyte Page: 1 of 6 Last Review Date: September 18, 2015 Valcyte Description Valcyte
More informationSince the initial descriptions of Pneumocystis carinii pneu- cases per 100 person-years of follow time (incidence density
1126 Risk Factors for Primary Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus Infected Adolescents and Adults in the United States: Reassessment of Indications for Chemoprophylaxis Jonathan
More informationChildren infected with the human immunodeficiency. Cardiac Dysfunction and Mortality in HIV-Infected Children
Cardiac Dysfunction and Mortality in HIV-Infected Children The Prospective P 2 C 2 HIV Multicenter Study Steven E. Lipshultz, MD; Kirk A. Easley, MS; E. John Orav, PhD; Samuel Kaplan, MD; Thomas J. Starc,
More informationPrognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-saharan Africa: a collaborative analysis of scale-up programmes
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-saharan Africa: a collaborative analysis of scale-up programmes Margaret May, Andrew Boulle, Sam Phiri, Eugene Messou,
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationSan Francisco AIDS Cases Reported Through December 31, 1998
San Francisco AIDS Cases Reported Through December 31, 1998 San Francisco Department of Public Health HIV Seroepidemiology and Surveillance Section AIDS Surveillance Unit Contents Page Commentary: Trends
More informationTransfusion-Induced Immunomodulation and Its Possible Role in Cancer Recurrence and Perioperative Bacterial Infection
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 63 (1990), 429-433 Transfusion-Induced Immunomodulation and Its Possible Role in Cancer Recurrence and Perioperative Bacterial Infection NEIL BLUMBERG, M.D.,a AND
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More information